#United States #New York #healthcare #biotechnology #Insmed

Insmed's Upcoming Investor Conference Presentations

Insmed Incorporated, a leading global biopharmaceutical firm based in Bridgewater, New Jersey, is set to make significant presentations during September 2026. The company is focusing on highlighting its innovative therapies aimed at transforming the lives of patients with serious diseases. On September 9, 2026, Insmed will participate in the 12th Annual Cantor Fitzgerald Global Healthcare Conference at 8:00 a.m. ET, followed by a presentation at the 24th Annual Morgan Stanley Global Healthcare Conference on September 14, 2026, at 2:35 p.m. ET.

These presentations are an opportunity for Insmed's management to engage with the investment community and provide updates on their advancements in biopharmaceutical therapies. The company is recognized for its commitment to developing first- and best-in-class therapies that positively affect patients battling chronic and debilitating conditions, particularly in respiratory health.

A Leader in Biopharmaceutical Innovation

Insmed specializes in discovering and delivering innovative therapies. With a diverse portfolio of both approved and investigational medicines, they currently focus on essential therapeutic areas, including:

• - Respiratory Health: Addressing chronic, debilitating lung diseases which significantly impact patients' quality of life.
• - Immunology & Inflammation: Developing therapies that target immune-related disorders.
• - Neuro & Rare Conditions: Researching treatments for other rare diseases and neurological conditions.

The company aims to ensure that their therapies meet the needs of patient communities requiring urgent treatment options. Their technological advancements include developing cutting-edge program technologies and methodologies, such as gene therapy and AI-driven protein engineering, which are indicative of their forward-thinking approach.

Commitment to Patient-Centric Care

Insmed proudly touts a people-first philosophy, with a primary goal of improving patient care through innovative medicines. Their research is designed not only to advance scientific frontiers but also to enhance the patient experience significantly. Over the years, Insmed has garnered recognition as a top employer within the industry, reflecting its commitment to employee satisfaction and the overall well-being of its workforce, further enabling the company to fulfill its mission of patient care.

During these upcoming conferences, stakeholders, investors, and media representatives will get live access to the presentations via webcasts. Furthermore, these webcasts will be archived for 30 days post-event, ensuring broad access to their updates and findings.

Insmed's headquarters in New Jersey, along with its international offices and research locations across Europe and Japan, underscores its global outreach and influence in the biopharmaceutical sector. As a recognized leader in the industry, Insmed continues to push the envelope, aiming for breakthroughs that can lead to substantial improvements in patients' health outcomes.

For more detailed information about the company and its future events, interested parties are invited to visit the investor relations section of Insmed's website at www.insmed.com. This is a unique opportunity for investors and stakeholders to engage with one of the foremost innovators in biopharmaceutical solutions.

In conclusion, Insmed's presentations at the upcoming investor conferences will not only shed light on their latest advancements in therapeutic innovations but also emphasize their ongoing commitment to enhance patient lives through persistent efforts in biopharmaceutical research and development.